Edition:
United States

Spectrum Pharmaceuticals Inc (SPPI.OQ)

SPPI.OQ on NASDAQ Stock Exchange Global Select Market

7.38USD
23 Jun 2017
Change (% chg)

$0.00 (+0.00%)
Prev Close
$7.38
Open
$7.39
Day's High
$7.45
Day's Low
$7.25
Volume
468,882
Avg. Vol
229,579
52-wk High
$7.99
52-wk Low
$3.21

Latest Key Developments (Source: Significant Developments)

Spectrum Pharmaceuticals reports Q1 loss per share $0.29
Tuesday, 2 May 2017 04:02pm EDT 

May 2 (Reuters) - Spectrum Pharmaceuticals Inc :Spectrum Pharmaceuticals reports first quarter 2017 financial results and pipeline update.Q1 non-gaap loss per share $0.14.Q1 loss per share $0.29.Q1 revenue $29.1 million versus i/b/e/s view $32.2 million.Q1 earnings per share view $-0.20 -- Thomson Reuters I/B/E/S.Spectrum Pharmaceuticals Inc - company ended quarter with cash and cash equivalents of $137 million..  Full Article

Spectrum Pharmaceuticals announces initiation of a phase 2 trial of Poziotinib
Thursday, 30 Mar 2017 07:00am EDT 

Spectrum Pharmaceuticals Inc : Spectrum Pharmaceuticals announces initiation of a phase 2 trial of Poziotinib in non-small cell lung cancer patients with EGFR exon 20 insertion mutations .Top-Line results are expected before year-end.  Full Article

Spectrum Pharmaceuticals reports Q4 loss per share of $0.22
Wednesday, 8 Mar 2017 04:02pm EST 

Spectrum Pharmaceuticals Inc : Spectrum Pharmaceuticals reports fourth quarter 2016 and full year 2016 financial results and pipeline update . Q4 non-GAAP loss per share $0.10 . Q4 loss per share $0.22 . Q4 revenue $35.2 million versus I/B/E/S view $31.1 million . Q4 earnings per share view $-0.27 -- Thomson Reuters I/B/E/S .Says Rolontis(eflapegrastim) pivotal program is on track for spectrum to file BLA next year.  Full Article

Spectrum Pharma receives complete response letter from FDA for Qapzola
Friday, 18 Nov 2016 06:37am EST 

Spectrum Pharmaceuticals Inc : Spectrum Pharmaceuticals Inc says on November 15, 2016, company met with FDA to discuss strategy for further development of Qapzola . Spectrum Pharmaceuticals - Based on discussions with FDA, co evaluating new smaller study that would replace ongoing phase 3 program . Spectrum Pharmaceuticals -On November 17 received complete response letter from FDA with respect to NDA for Qapzola Source: (http://bit.ly/2g1VIog) Further company coverage: [SPPI.O] ((bangalore.newsroom@thomsonreuters.com;)).  Full Article

Spectrum pharmaceuticals posts Q3 loss per share of $0.22
Monday, 14 Nov 2016 07:00am EST 

Spectrum Pharmaceuticals Inc : Spectrum Pharmaceuticals Inc says total product sales were $30.3 million in Q3 of 2016 . Q3 non-gaap loss per share $0.07 . Q3 earnings per share view $-0.30 -- Thomson Reuters I/B/E/S . Spectrum Pharmaceuticals provides third quarter financial update .Q3 loss per share $0.22.  Full Article

Spectrum Pharma Q2 non-gaap loss per share $0.05
Tuesday, 9 Aug 2016 04:00pm EDT 

Spectrum Pharmaceuticals Inc : Q2 loss per share $0.35 . Q2 earnings per share view $-0.29 -- Thomson Reuters I/B/E/S . Spectrum pharmaceuticals reports second quarter 2016 financial results and pipeline update . Q2 non-gaap loss per share $0.05 .Q2 revenue $33.9 million versus i/b/e/s view $30.9 million.  Full Article

Spectrum says unit Allos Therapeutics and Fresenius Kabi USA reach settlement to resolve patent litigation
Wednesday, 13 Jul 2016 06:55am EDT 

Spectrum Pharmaceuticals Inc : Spectrum says unit Allos Therapeutics and Fresenius Kabi USA entered into settlement agreement to resolve patent litigation relating to Folotyn . Details of settlement are confidential, parties will submit agreement to Federal Trade Commission and Department of Justice . Says Fresenius will be permitted to market a generic version of Folotyn In United States On November 15, 2022- Sec filing . Says parties will request that court enter an order, in which it will dismiss company's litigation against Fresenius .Says Fresenius was last remaining defendant in litigation, which accordingly is expected to conclude.  Full Article

Spectrum Pharmaceuticals' unit, Allos Therapeutics and Sandoz enter settlement agreement
Thursday, 9 Jun 2016 06:15am EDT 

Spectrum Pharmaceuticals Inc : On June 8, 2016, co's unit , Allos Therapeutics and Sandoz Inc entered into a settlement agreement . Spectrum Pharmaceuticals Inc says settlement agreement to resolve patent litigation relating to folotyn . Sandoz will be permitted to market generic version of folotyn in U.S on November 15, 2022 or earlier under certain circumstances . Details of settlement confidential, parties will submit agreement to ftc and department of justice . Spectrum Pharmaceuticals says parties will request that court enter an order, in which it will dismiss company's litigation against sandoz .Spectrum Pharmaceuticals Inc says company's litigation against one other generic filer continues.  Full Article

Spectrum Pharma says Dr Reddy's will be permitted to market generic version of Folotyn in US on Dec 1, 2022 or earlier
Tuesday, 31 May 2016 07:02am EDT 

Spectrum Pharmaceuticals : Co's unit, dr. Reddy's labs, ltd entered into settlement agreement to resolve their patent litigation relating to folotyn .dr. Reddy's will be permitted to market generic version of folotyn in u.s. On december 1, 2022 or earlier under certain circumstances.  Full Article

Spectrum Pharma says unit, Teva enter settlement agreement
Wednesday, 25 May 2016 07:06am EDT 

Spectrum Pharmaceuticals Inc : Unit, teva pharmaceuticals usa, inc. Entered into settlement agreement to resolve patent litigation relating to Folotyn . Teva will be permitted to market generic version of folotyn in u.s. On december 1, 2022 or earlier under certain terms . Details of settlement are confidential, and parties will submit agreement to federal trade commission and doj .Parties will request that court enter an order, in which it will dismiss company's litigation against teva.  Full Article

More From Around the Web

BRIEF-Spectrum Pharmaceuticals says stockholders did not approve by advisory vote executive compensation at annual meeting

* Spectrum Pharmaceuticals Inc - stockholders did not approve by advisory vote executive compensation at annual meeting Source text: (http://bit.ly/2sHq6yo) Further company coverage: